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OBJECTIVES: The impact of Chagas disease (CD) in HIV-infected patients is relevant throughout the world.
In fact, the characterization of the adaptive immune response in the context of co-infection is important for
predicting the need for interventions in areas in which HIV and Chagas disease co-exist.
METHODS: We described and compared the frequency of cytokine-producing T cells stimulated with soluble
antigen of Trypanosoma cruzi (T. cruzi) using a cytometric assay for the following groups: individuals with
chronic Chagas disease (CHR, n=10), those with Chagas disease and HIV infection (CO, n=11), those with only
HIV (HIV, n=14) and healthy individuals (C, n=15).
RESULTS:We found 1) a constitutively lower frequency of IL-2+ and IFN-g+ T cells in the CHR group compared
with the HIV, CO and healthy groups; 2) a suppressive activity of soluble T. cruzi antigen, which down-regulated
IL-2+CD4+ and IFN-g+CD4+ phenotypes, notably in the healthy group; 3) a down-regulation of inflammatory
cytokines on CD8+ T cells in the indeterminate form of Chagas disease; and 4) a significant increase in IL-10
+CD8+ cells distinguishing the indeterminate form from the cardiac/digestive form of Chagas disease, even in
the presence of HIV infection.
CONCLUSIONS: Taken together, our data suggest the presence of an immunoregulatory response in chronic
Chagas disease, which seems to be driven by T. cruzi antigens. Our findings provide new insights into
immunotherapeutic strategies for people living with HIV/AIDS and Chagas disease.
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’ INTRODUCTION
Chagas disease (CD), caused by the protozoan Trypano-
soma cruzi (T. cruzi), which is transmitted to humans by a
vector (reduviid bugs), is currently one of the most important
neglected diseases in Latin America. After the control of
transmission by Triatoma infestans, the main vector in Brazil,
the most important route is oral transmission associated with
acute cases and outbreaks (1). Migration from rural areas has
made chronic CD primarily an urban disease in Latin America
and the United States (1-6). Transmission of CD through
blood transfusion, blood by-products, or organ transplanta-
tion is currently a serious problem in non-endemic areas.
At least 5 to 6 million chronically infected individuals live
in endemic and non-endemic countries, and the disease con-
tinues to represent a health threat around the world (6).
Acute CD is characterized by alterations in the mono-
nuclear phagocytic system, causing lymphadenopathies and,
less frequently, severe myocarditis or meningoencephalitis.
Additionally, although most chronically infected individuals
are asymptomatic, approximately 30 to 40% develop recog-
nized cardiomyopathy or gastrointestinal tract disorders (7).
Reactivation of CD manifests as a febrile syndrome
with meningoencephalitis and/or myocarditis, which is alsoDOI: 10.6061/clinics/2017(11)02
Copyright & 2017 CLINICS – This is an Open Access article distributed under the
terms of the Creative Commons License (http://creativecommons.org/licenses/by/
4.0/) which permits unrestricted use, distribution, and reproduction in any
medium or format, provided the original work is properly cited.
No potential conflict of interest was reported.
652
CLINICAL SCIENCE
associated with HIV infection and other immunodeficiency states
such as haematological malignancies, bone marrow, kidney, or
heart transplantation, and corticosteroid therapy (8-11). Reactiva-
tion of CD in AIDS patients has been observed in p20% of
co-infected patients and has sometimes been reported as the first
opportunistic infection (12). According to Almeida et al. 2011 (13),
the overall mortality rate of HIV patients was 30%, and mortality
occurred in 73% of the cases inwhich therewas reactivation of CD.
The frequency of individuals co-infected with HIV and
T. cruzi was estimated at 1.3% in a Brazilian study with a
macro-regional approach (14). The impact of co-infection is
extremely relevant, as approximately 1.5 million individuals
with HIV/AIDS live in Latin America and approximately
21,420 HIV/T. cruzi co-infected patients are estimated to live
in this area (15).
Immunoregulatory mechanisms may influence the patho-
genesis and clinical evolution of CD (16). Because CD and
HIV infection are both associated with T cell responses and
disturbances of cytokine networks (17, 18), the characteriza-
tion of cytokine-secreting T cells is particularly relevant to
improving our understanding of the immunopathogenesis of
CD and to controlling concomitant intracellular infections in
AIDS and other immunosuppressive conditions. A study of
the differential regulation of Th1 and Th2 responses in HIV
infection showed that decreased secretion of type-1 cyto-
kines, such as IL-2 and IFN-g, was associated with a higher
susceptibility to opportunistic infections (19). Conversely,
previous studies of the pathogenesis and clinical evolution of
CD have reported higher IL-4/IFN-g ratios in patients with
HIV/Chagas disease as well as the preferential involvement
of inflammatory cytokines and activated T cells (18, 20).
However, it is unclear whether the presence of HIV and
T. cruzi co-infection modifies this mechanism in humans.
Recent studies have demonstrated the impact of a specific
antigenic stimulus on the course of a chronic infection in
mice, as seen in the association between an HIV vaccine and
helminthic infection (21). Accordingly, the characterization of
the adaptive immune response either in mouse models or in
human infections is relevant to interpreting or predicting
therapeutic interventions in endemic areas where HIV and
other infections co-exist.
This study aimed to describe and compare the profiles
of cytokine-producing T cells from individuals with chronic
Chagas disease and/or HIV infection with those from healthy
individuals using a cytometric assay, which detects the intra-
cellular accumulation of cytokines in CD4+ and CD8+
T lymphocytes stimulated with soluble trypomastigote anti-
gens and mitogens.
’ MATERIALS AND METHODS
Ethics Statement
The Human Research Ethics Committee of the Hospital
das Clínicas, Faculdade de Medicina, University of São Paulo
approved the research protocol (CAPPesp 010/95-B). A signed
informed consent form was obtained from all 50 participants
(35 patients diagnosed with CD and/or HIV infection and
15 healthy individuals) for the period of 2001-2005 to partici-
pate in the present cross-sectional study based on convenience
sampling.
Study Groups and Methods
We enrolled 35 patients diagnosed with chronic CD and/or
HIV infection who attended the Outpatient Clinic, Division
of Clinics of Infectious and Parasitic Diseases of the Hospital
das Clínicas, Faculdade de Medicina, University of São Paulo.
HIV infection was diagnosed with ELISA and confirmed
with Western blotting. CD4+ and CD8+ T cell counts
were measured by flow cytometry, and HIV viral load was
determined by polymerase chain reaction (PCR). All HIV-
infected individuals received Highly Active Antiretroviral
Therapy (HAART), according to the national guidelines
for antiretroviral therapy (15). For CD diagnosis (the CHR
group), seropositivity in at least two of three tests for T. cruzi
infection (i.e., ELISA, indirect immunofluorescence assay,
and indirect haemagglutination assay) was required. The
clinical forms of CD were classified according to Sartori et al.
2007 (22): (1) ‘‘Indeterminate form’’ (IND), meaning no symp-
toms or signs and normal results for electrocardiogram
(ECG), chest X-ray, and oesophagography. (2) ‘‘Non-typical
cardiopathy’’ or ‘‘atypical manifestations’’ (AT), meaning ECG
changes possibly related to conditions other than CD. (3)
‘‘Typical cardiopathic form’’ with ECG changes considered
typical of CD, including sinus bradycardia o50 beats/min,
right bundle-branch block, second-degree atrioventricular
block, and/or complex ventricular arrhythmia. (4) ‘‘Digestive
form’’, meaning megaoesophagus or megacolon. (5) ‘‘Typical
digestive and cardiopathy’’ (TDC), meaning typical cardiac
and/or digestive manifestation. Xenodiagnosis (23) and
blood culture (24) were requested according to medical
orientation and performed by the Laboratory of Parasitology
of the Clinics Hospital. Blood culture and/or xenodiagnosis
data were used to confirm the presence or absence of para-
sites (T. cruzi) or reactivation of infection by T. cruzi at the
time of this study. Qualitative PCR was performed using
primer pairs for S35 and S36 kinetoplast sequences (25).
Qualitative PCR was also performed using TCZ3/TCZ4
microsatellite sequences (26).
Therefore, we analysed four groups. There were 10 indivi-
duals with chronic CD and not infected with HIV (CHR
group), 11 with chronic CD and HIV infection (CO group),
14 with HIV infection without CD (HIV group) and 15 healthy
individuals (C group). The C group consisted of individuals
reporting the absence of CD, HIV diagnosis or any other
chronic or acute illnesses, with CD4+ and CD8+ levels
above those associated with susceptibility to opportunistic
diseases (4500 cells/mm3) and aged o50 years old.
We assessed the frequencies of CD4+ or CD8+ T cells
staining positive for IL-2, IFN-g, IL-4, and IL-10 after being
incubated in vitro with SAg and/or mitogens (phorbol and
ionomycin), according to the methods described below.
Concerning the available data on the clinical form of CD in
individuals with or without HIV infection, we compared two
sub-groups of CD: typical digestive and/or cardiac manifes-
tation (TDC) (n=8) and indeterminate form (IND) (n=8). Two
patients with an atypical clinical (AT) form of CD and three
with an unknown or non-identified (NI) form of CD were
excluded from these analyses.
Cell Preparation and In Vitro Stimulation with Soluble
Antigen of T. cruzi Trypomastigote (SAg)
Samples of peripheral blood mononuclear cells (PBMCs)
were isolated from heparinized venous blood (30 mL) using
density gradient sedimentation (1.077 g/mL) in accordance
with the recommendations of the manufacturer (Ficoll-Paque -
Amersham Bioscience, Piscataway, NJ, USA). The cells were
then washed three times with sterile phosphate-buffered
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saline (PBS) without Mg++/Ca++ (Gibco BRL, UK) and
re-suspended at 2.5 x 106 cells/mL in RPMI 1640 (Gibco BRL,
UK) supplemented with 10% heat inactivated foetal calf serum
(HyClone, Logan, Utah, USA), 2 mM L-glutamine (Gibco
BRL, UK) and antibiotics, according to Sousa e Victorino,
(1998) (27) for in vitro stimulation and immunofluorescence
staining of freshly isolated cells.
The soluble antigen obtained by complete disruption of
1.0 x 106 parasites/mL (10 cycles of freezing and thawing at
the trypomastigote stage) was kindly provided by Dr. Ises
de Almeida Abrahamsohn (Department of Immunology of
the Institute of Biomedical Sciences of the University of São
Paulo, SP, Brazil).
Two different antigenic stimuli were used to stimulate cells
in vitro, according to De Barros-Mazon et al. (2004) (20),
but with some modifications. One set of cells was stimulated
with specific soluble trypomastigote antigen (SAg) for 72 hours
followed by brefeldin A (BFA, Sigma Chemical) at a final con-
centration of 10 mg/ml and phorbol 12-myristate 13-acetate
(PMA, Sigma Chemical) + ionomycin (I, Sigma Chemical)
at a final concentration of 50 ng/mL and 500 ng/mL, respec-
tively, for the last 4 hours. In addition, another sample of
cells was subjected to the same protocol with only PMA+I+
BFA and not SAg to measure the potential capability of each
cell to produce these cytokines. It has been shown that
following stimulation of lymphocytes with PMA and ionomy-
cin, a rapid down-regulation of CD4 molecules on the surface
of lymphocytes occurs (28). In our hands, a rapid decrease in
CD4 occurred within 4 hours after stimulation. Therefore,
a negative-gating strategy (among CD3+ T cells, CD8- cells
were selected) was used to measure the intracellular cytokine
expression in CD3+CD4+ cells. To normalize the comparison
of inter-assay results, each assay analysed PBMCs from
individuals in the four groups, with at least one individual of
each group (C, CO, HIVand CHR) measured simultaneously.
Monoclonal Antibodies (MoAbs) for Intracellular
and Cell Surface Staining
The following phycoerythrin-conjugated anti-human cyto-
kines and corresponding isotype controls were used for each
antibody and each patient: anti-IL-2, clone M062626; anti-
IFN-g, clone M064882; anti-IL-4, clone M064843; anti-IL-10,
clone M063277; rat IgG2a, clone M063752; and mouse IgG1,
clone M056389. Surface staining was performed with anti-CD3
phycoerythrin-cyanin 5 (PE-Cy5), clone M047602, and anti-CD8
fluorescein isothiocyanate (FITC), clone M055034. All anti-
bodies were purchased from Pharmingen (San Diego, CA).
Figure 1 - Flow cytometric evaluation. (A) T. cruzi-stimulated cells. Lymphocytes in the R1 region based on the SSC/FSC (Side Scatter/Forward
Scatter) ratio; (E) CD3 surface marker staining on lymphocytes gated in R1; (B, C, D, F, G, H) CD8 surface- and intracellular IFN-g-stained cells
were simultaneously gated in R1 (lymphocytes) and R2 (CD3+ cells). R3 and R5 regions represent CD8+ and CD8- (i.e.: CD4+) cells negative
for IFN-g, respectively; R4 and R6 represent CD8+IFN-g+ and CD4+IFN-g+ cells, respectively. Peripheral blood mononuclear cells were
cultured for 72 h without T. cruzi antigen (B, C, D) and with T. cruzi antigen (F, G, H) and subsequently exposed to PMA, ionomycin, and
brefeldin A (BFA) for the last 4 h. For each analysis, approximately 50,000 events were acquired on a FACSCalibur flow cytometer.
(B) Monocyte gate strategy. Flow cytometric acquisition and subsequent analysis were manually performed within a monocyte gate defined
for each sample using CellQuest (BD Bioscience, Immunocytometry System) based on a higher FSC/SSC ratio and negative expression of CD3
and CD8 (R7 region) and are displayed as histograms showing cytokines (PE) (R8 region).
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Immunofluorescence Staining and Flow Cytometric
Analyses
Cells were washed in PBS with 0.1% sodium azide (PBS-
azide). First, the Fc receptors of the cells were blocked with
2 mg of human IVIg (50 mg/ml) and incubated for 20 minutes
at room temperature to decrease non-specific staining. Next,
the cells were washed in PBS-azide and re-suspended in
PBS (Gibco, without Ca+ and Mg+) with 1% bovine serum
albumin (BSA, Sigma) and 0.1% sodium azide (Azide) (stain-
ing buffer). After surface staining with anti-CD8 and anti-
CD3 MoAbs, the cells were washed with staining buffer and
fixed with PBS-1% paraformaldehyde (fixation buffer). These
steps were performed at 4oC in the dark. Subsequently, the
cells were permeabilized with PBS with 1% BSA and 0.5%
saponin (permeabilization buffer). Intracellular staining was
performed by incubation with anti-IL-2, anti-IL-4, anti-IL-10,
and anti-IFN-g MoAbs or respective isotype controls for
30 minutes at room temperature in the dark. Next, the cells
were washed and re-suspended in PBS-azide for flow
cytometric analysis.
For each analysis, approximately 50,000 events were acquired
on a FACSCalibur flow cytometer (Becton-Dickinson, San
Jose, CA, USA). Flow cytometric acquisition was performed
within a lymphocyte gate defined for each sample using
CellQuest (BD Bioscience, Immunocytometry System) and
displayed as dot plots showing cytokines (PE) versus CD3
(PE-Cy5) and CD8 (FITC) fluorescence in multiple dot plots.
The CD8 dot plot was analysed for double dependence and
CD3 expression on an FSC-SSC lymphocyte gate (Figure 1,
Figure 1A). The monocyte gate was determined by FSC-SSC
and exclusion of CD3+ and CD8+ populations (Figure 1,
Figure 1 B).
Statistical Analysis
For comparisons between two groups, the Mann-Whitney
test was used. For within-group comparisons, the Wilcoxon
test was used. For comparisons among three groups (HIV, C
and CHR), the Kruskal Wallis test was used. Statistical signi-
ficance was set at 5% (po0.05). The Spearman correlation
coefficient was used to measure bivariate associations of the
proportion of cytokines.
’ RESULTS
Clinical and Laboratory Data of the Study Groups
Data regarding the clinical groups at the time of enrolling
in the study are shown in Table 1.
The median age distribution was 30, 40, 47 and 42 years
old for the C, HIV, CO and CHR groups, respectively.
The proportion of male participants was lower in the CHR
group (30.0%) than in the CO group (54.5%) and HIV group
(78.6%), but the differences did not reach statistical sig-
nificance among these groups (Kruskal Wallis test, p=0.9639).
There was an equal proportion of females in the CHR group
and C group (70-73%). Moreover, there was no difference in
the CD4+ cell count among the HIV, CO and CHR groups
(Kruskal Wallis test, p=0.0921) (Table 1A).
The distribution of CD sub-groups and the mean CD4+
cell count among individuals with positive (n=4) and
negative parasitaemia (n=11) detected by haemoculture,
xenodiagnosis and PCR were also presented. PCR analysis
for parasite DNA fragments was positive in two chagasic
individuals with HIV infection (CO group) of eight avail-
able plasma samples. The CD4+ cell count tended to be
higher in individuals with negative parasitaemia than with
positive parasitaemia, but without statistical significance
(Table 1B).
Table 1A - Study groups according to CD4+ cell count, age, sex and sub-groups of Chagas disease.
Variables groups C HIV CO CHR
n 15 14 11 10
CD4+ count /cells/mm3 median (min-max) 961 (933-988) 475 (243-870) 505 (218-837) 855 (551-1198)
Age years (median) 30 40 47 42
Female % 73.0 21.4 45.5 70.0
Subgroups of CD
TDC n NA NA 4 4
IND n NA NA 4 4
AT n NA NA 2 0
NI n NA NA 1 2
min=minimum; max=maximum; n=number of individuals; CD=Chagas disease; C=healthy controls; HIV=HIV infection; CO=co-infected with Chagas disease
and HIV; CHR=chronic Chagas disease; TDC=typical digestive and/or cardiac involvement; IND=indeterminate form of CD; AT=atypical form of CD; NI=not
identified; NA=not applied; (SD)=standard deviation; n=number of patients.
Table 1B - CD4 cells/mm3 in 15 Chagas disease individuals (ALL)
according to the presence of parasitaemia (detected by PCR,
haemoculture and xenodiagnoses).
ALL Chagas disease Positive
parasitemia
Negative
parasitemia
Disease form
(Number of Patients)
n n
CO and IND 1 3
CO and TDC 1 4
CHR and IND 1 2
CHR and TDC 1 1
CHR and NI 0 1
HIV viral load (copies/mL)
Mean (SD) 3.6 (3.5)a 4.3 (4.1)b
Indetectable (%) 25.0 66.7
Mean (SD) CD4 cells/mm3 361 (166)c 680 (278)c
Total Number of Patients 4 11
CD=Chagas disease; C=healthy controls; HIV=HIV infection; CO=co-infected
with Chagas disease and HIV; CHR=chronic Chagas disease; TDC=typical
digestive and/or cardiac involvement; IND=indeterminate form of CD;
AT=atypical form of CD; NI=not identified; (SD)=standard deviation;
n=number of patients.
a two with available HIV viral load data.
b six with available HIV viral load data.
cp40.05 between CD4+ cells of positive and negative parasitaemia
patients (Mann-Whitney test).
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Figure 2 - Comparison of the potential capability of T cells to produce cytokines. (A-D) Proportion of cytokines on CD4+ T cells. (E-H)
Proportion of cytokines on T CD8+ T cells. C = healthy controls; HIV = HIV infection; CO = co-infected with Chagas disease and HIV;
CHR = chronic Chagas disease. IL-2+CD4+ phenotype: a statistically significant difference was observed between the CHR and
HIV groups (Mann-Whitney test, p=0.0322), the CHR and C groups (Mann-Whitney test, p=0.0011), and the CHR and CO groups
(Mann-Whitney test, p=0.0049). IL-2+CD8+ phenotype: a statistically significant difference was observed between the CHR and HIV
groups (Mann-Whitney test, p=0.0441) and between the CHR and C groups (Mann-Whitney test, p=0.0436). IFN-g+CD4+ phenotype:
a statistically significant difference was observed between the CHR and C groups (Mann-Whitney test, p=0.0101) and between the
CHR and CO groups (Mann-Whitney test, p=0.0153). No statistically significant differences were observed in relation to the other
phenotypes.
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Comparison of the Phenotype Frequency of Cytokines
on CD4+ and CD8+ T cells from the C, HIV, CO, and
CHR Groups
In the Absence of SAg Antigen. The potential capacity
of production of IL-2+ and IFN-g+ Tcells in the CHR groupwas
low, as determined by comparing the CHR group with each other
group (C, HIV, CO) and shown in Figure 2 (Figure 2A, 2B, 2E).
No significant differences were found in other cellular phenotypes
(Figure 2C, 2D, 2F, 2G, 2H).
In the Presence of In Vitro SAg Stimulation. When we
compared cells stimulated and non-stimulated with SAg
from healthy individuals (group C) in particular, we observed
a reduced proportion of IL-2+CD4+ and IFN-g+CD4+ cells
in the presence of SAg, as shown in Figure 3 (Figure 3A,
Figure 3B). We found no significant differences when we
compared other Tcell phenotypes from the CO, CHR and HIV
groups in the presence or absence of SAg.
Comparison between the Indeterminate Form and
Typical Clinical Manifestation of CD
The results indicated a differential frequency of cell pheno-
types between the IND and TDC sub-groups of CD (n=16),
as shown in Figure 4.
In Both the TDC (n=8) and IND (n=8) sub-groups, half
of the patients were HIV-infected patients with low or
undetectable viral load. In addition, six positive parasitolo-
gical tests were detected in the sub-groups of CD.
In the absence of SAg, the frequencies of IL-2+CD8+ and
IL-10+CD8+ phenotypes were higher in sub-group IND
than in sub-group TDC (Mann-Whitney test, p=0.0080 and
0.0426, respectively). Conversely, the frequency of the IL-2
+CD8+ phenotype in IND was lower in the absence of SAg
than in the presence of SAg (IND and IND*, Wilcoxon test,
p=0.0078). Furthermore, in the presence of cellular stimula-
tion by SAg, the proportion of IFN-g+CD8+ cells was lower
in IND than in TDC (Mann-Whitney test, p=0.0464). Similarly,
we observed that the frequency of this phenotype was signi-
ficantly lower in all chagasic individuals, even in those
co-infected with HIV (ALL and ALL*, Mann-Whitney test,
p=0.0317, Figure 4).
We also found a negative correlation between IFN-g and
IL-10 (p=0.0390; r=-0.6691) when the source of cytokines was
CD8+ T cells derived from chronic chagasic patients.
’ DISCUSSION
We have described the profile of intracellular cytokine
production in T cells from HIV-infected and/or chagasic
individuals by focusing on three important aspects, showing
that T. cruzi exposure played a pivotal role in the down-
regulation of inflammatory cytokine-producing T cells in
human infections.
First, we showed that the potential capability of T cells
to produce IL-2 and IFN-g was lower in individuals with
chronic CD compared with each of the other groups analysed
(HIV, CO or C). IL-2 has been described as a prototypic Th1
cytokine, being essential for the differentiation and activation
of regulatory T cells, and as noted here, the decreased IL-2
production in chronic CD seems to suggest that an adap-
tive activation mechanism is triggered by prior exposure to
T. cruzi infection (Figure 2, Figure 2A, 2B and 2E). The
decreased inflammatory profile could be associated with
the pathogenesis of cardiac and gastrointestinal diseases, since
the immunoregulatory features seem to be linked to the
indeterminate form of CD (29, 30).
Second, we observed in vitro an immunomodulatory effect
of SAg, mainly expressed in cells from healthy individuals.
In fact, a significant down-regulation of IL-2+CD4+ and
IFN-g+CD4+ cells was observed in healthy individuals
(group C), who reported the absence of acute or chronic
disease and did not belong to the risk group exposed to
T. cruzi or HIV infection (Figure 3, Figure 3A, Figure 3B).
We observed the absence of this effect in the CHR group, as
these cell phenotypes were already low at background level
in these patients. Corroborating our data, other protocols
based either on soluble antigen or on cell cultures stimulated
by living trypomastigotes suggest that this effect of the HIV-
T. cruzi interaction on cytokine secretion is parasite driven
(31, 32). By contrast, protocols based on cellular stimulation
with epimastigotes or recombinant B13 antigen do not seem
Figure 3 - Comparison of the proportion of cytokines on T cells with and without SAg stimulus. (A). IL-2+CD4+. (B) IFN-c+CD4+.
The asterisk (*) represents the condition in which cells were stimulated with soluble T. cruzi antigen. The difference between non-
stimulated and stimulated* cells was significant for IL-2+CD4+ (Wilcoxon test, p=0.0093) and IFN-g+CD4+ T cells (Wilcoxon test,
p=0.048). No statistically significant differences were observed in relation to the other phenotypes.
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to induce a suppressive immune response like the response
observed in this study using trypomastigote antigen (20).
Third, despite the limited sample size, we observed a polar-
ized Th1 CD8+ T cell response when cells from chagasic
individuals were exposed in vitro to SAg stimuli, thus dis-
tinguishing the typical digestive/cardiac form (TDC group)
from the indeterminate form of CD (IND group) (Figure 4).
In the TDC group, we clearly verified an up-regulation of
inflammatory cytokines on CD8+ T cells challenged with
soluble trypomastigote antigen. However, the biased inflam-
matory response characterizing individuals with the cardiac
and/or digestive form of CD (33) could be justified by the
absence of the activation of a regulatory immune mechanism.
Moreover, the profile of cytokines observed in the IND sub-
group has been previously suggested to be a strategy that
improves the chances of parasite survival (28). Additionally,
CD8+ T cells seem to play a role in the balance between pro-
inflammatory responses to eradicate the pathogen and anti-
inflammatory responses to limit inflammation as described in
CD and other infections (34,35). In fact, the TDC sub-group
presented a lower frequency of IL-10+CD8+ cells and a
higher frequency of IFN-g+CD8+ cells than individuals with
the indeterminate form of CD (IND). This was especially true
for individuals with HIV infection (Figure 4, red points).
Nevertheless, studies on the source of IL-10 in humans are
conflicting, partly due to the different assessment methods
used (36,37,38). Thus, we also assessed the production of
IL-10 by monocytes with and without SAg stimulation,
but we did not find any significant difference between the
clinical groups (data not shown). On the other hand, we were
able to detect a significant difference between the IND and
TDC sub-groups in relation to the IL-10+CD8+ phenotype.
Our findings corroborate the fact that IL-10 produced by
T cells seems to act mainly as a regulatory cytokine to protect
the infected hosts against unwanted excessive Th1 activation
and severe inflammatory pathology (20,29,34).
Our patients exhibited a trend of higher IL-4 production
by SAg-stimulated CD4+ T cells in the co-infected (CO)
group compared with the HIV group, similar to the patients
studied by Rodrigues et al. (2005) (18). The percentage of
IL-4-producing CD4+ T cells stimulated by SAg varied from
zero to 27.47% with a median of 10.71% in the CO group,
while in HIV group, the same cell population was between
zero and 46.79% with a median of 0.0% (p=0.0957).
Moreover, the same tendency was noted by comparing the
CO and CHR groups, as the former tended to show higher
percentages of SAg-stimulated IL-4-producing CD4+ T cells
than the latter. The percentage of IL-4-producing SAg-
stimulated CD4+ T cells varied from zero to 27.47% with a
median of 10.71% in the CO group, while that of the CHR
group varied from zero to 20.84% with a median of 4.24%
(p=0.1108). This trend was not observed when we compared
the non-SAg-stimulated CD4+ T cells of the CO group with
those of the HIVor CHR groups. These data suggest that SAg
can induce the synthesis of IL-4 and that the co-infected group
is more sensitive to this stimulus.
Recently, studies have characterized the adaptive immune
response in different epidemiologic contexts. In fact, the
interference of previous exposure to a specific antigen (vacci-
nated or not) has been reported in both dual infections or
other models of infections involving HIV. In the infection
model of Schistosoma in mice, the suppression of the immune
response to a Th1-type HIV vaccine and impaired expansion
of pathogen-specific cytotoxic CD8+ T cell responses was
Figure 4 - Proportion of cytokine-producing CD8+ T cells in
chagasic sub-groups. (A) IL-2+CD8+. (B) IFN-c+CD8+. (C) IL-10+
CD8+. Patients were subdivided into a typical digestive and/or
cardiac manifestation (TDC) sub-group and a non-cardiac/non-
digestive manifestation of CD (IND) sub-group, and all chagasic
(TDC and IND) patients were identified as the ALL group.
The asterisk (*) represents the condition in which cells were
stimulated with soluble T. cruzi antigen. The TDC and IND sub-
groups had four HIV-infected individuals each. Red plots indicate
HIV-infected individuals. The Mann-Whitney test was used for
between-group comparisons (p indicated below the x-axis), and
the Wilcoxon test was used for within-group comparisons
(p indicated above the x-axis). The difference between TDC*
and IND* stimulated T cells to produce cytokines was significant
for the IFN-g+CD8+ phenotype (Mann-Whitney test p=0.0464).
The potential capability of T cells to produce cytokines was
different between TDC and IND for the IL-2+CD8+ phenotype
(Mann-Whitney test, p=0.0080) and the IL-10+CD8+ phenotype
(Mann-Whitney test, p=0.0426). No significant differences were found
in relation to the other phenotypes.
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reported (21). In addition, in children living with HIV, higher
CD4+ T cell activation leads to poor vaccine response,
which may be related to a disequilibrium of T regulatory
responses (39, 40). In infant macaques vaccinated with BCG
or M. tuberculosis, CD4+ T cells were persistently activated
in oral and/or gastrointestinal tissues, which may have
facilitated oral SIV infection, according to the authors (41).
Moreover, in HIV-infected Kenyan infants, higher central
memory Th1 responses to M. tuberculosis antigens were
observed at three months, but reduced effector memory
Th1 responses to vaccine antigens were seen at three and
12 months. Long-term monitoring of vaccine efficacy and T-cell
immunity in this vulnerable population is warranted (42).
Our study, however, has some important limitations.
First, because it was not possible to obtain serial CD4+ cell
counts, HIV viral loads or parasitological data, it would be
very useful to verify additional relationships with immune
responses. This fact is directly linked to the limited access
patients with CD have to medical assistance and diagnosis.
Second, our critical findings were based on a limited number
of available samples. However, we screened a rare and well-
characterized group of HIV and/or chagasic individuals.
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